Lymphocyte Predominant Hodgkin Lymphoma

• LPHL is a rare form of Hodgkin lymphoma, accounting for about 5-10% of all Hodgkin lymphoma cases.
• It is characterized by the presence of unique “popcorn cells” (L&H cells) in the lymph nodes.
• The most common symptom is a painless enlargement of lymph nodes, often without systemic “B symptoms.”
• Diagnosis relies on a lymph node biopsy and specific immunophenotyping.
• Treatment typically involves surgery, radiation, chemotherapy, or a combination, depending on the disease stage.

What is Lymphocyte Predominant Hodgkin Lymphoma (LPHL)?

Lymphocyte Predominant Hodgkin Lymphoma (LPHL) is a rare and distinct subtype of Hodgkin lymphoma, differing significantly from classical Hodgkin lymphoma (CHL) in its cellular characteristics, clinical behavior, and treatment approach. It accounts for approximately 5-10% of all Hodgkin lymphoma cases, as reported by organizations like the Lymphoma Research Foundation. LPHL is primarily characterized by the presence of unique malignant cells known as lymphocytic and histiocytic (L&H) cells, often referred to as “popcorn cells” due to their appearance. These cells are typically found within a background rich in small lymphocytes, rather than the Reed-Sternberg cells characteristic of CHL.

LPHL commonly affects younger individuals, particularly males, and often presents as localized disease. Unlike CHL, LPHL cells typically express the CD20 protein but lack CD15 and CD30, which are usually present in CHL. This specific immunophenotype is critical for accurate diagnosis. The disease generally has an excellent long-term prognosis, especially when diagnosed at an early stage, though it can sometimes recur or, in rare instances, transform into an aggressive non-Hodgkin lymphoma.

Symptoms and Diagnosis of Lymphocyte Predominant Hodgkin Lymphoma

The most common lymphocyte predominant hodgkin lymphoma symptoms involve the painless enlargement of lymph nodes. These swollen nodes are typically found in the neck, armpit (axilla), or groin area. Unlike classical Hodgkin lymphoma, systemic symptoms, often referred to as “B symptoms” (such as unexplained fever, drenching night sweats, and significant unintentional weight loss), are less frequently observed in individuals with LPHL. Other less common symptoms might include fatigue or itching, but these are not as defining as the localized lymphadenopathy.

The definitive diagnosis of lymphocyte predominant hodgkin lymphoma requires a biopsy of the affected lymph node. During this procedure, a tissue sample is removed and examined under a microscope by a pathologist. The presence of characteristic L&H cells, along with their specific immunophenotype (CD20 positive, CD15 and CD30 negative), confirms the diagnosis. Imaging tests, such as CT scans or PET scans, are often used to determine the extent or stage of the disease, identifying all affected lymph nodes or potential spread. In some cases, a bone marrow biopsy may be performed, though bone marrow involvement is less common in LPHL compared to other lymphomas.

Common symptoms of LPHL include:

• Painless swollen lymph nodes (neck, armpit, groin)
• Less common: fatigue, itching
• Rarely: B symptoms (fever, night sweats, weight loss)

Treatment Options for Lymphocyte Predominant Hodgkin Lymphoma

Lymphocyte predominant hodgkin lymphoma treatment strategies are tailored based on the disease stage, the patient’s age, overall health, and whether the disease is newly diagnosed or recurrent. Due to its distinct biology, LPHL often responds differently to therapies compared to classical Hodgkin lymphoma. For early-stage, localized LPHL, treatment may involve surgical excision of the affected lymph node, sometimes followed by radiation therapy to the involved area. This localized approach can be highly effective in achieving remission.

For more advanced stages of LPHL, or if the disease recurs, systemic treatments are typically employed. Chemotherapy regimens, often similar to those used for non-Hodgkin lymphoma, may be administered. Given that L&H cells express CD20, immunotherapy with an anti-CD20 monoclonal antibody, such as rituximab, is frequently used, either alone or in combination with chemotherapy. The choice of treatment aims to maximize efficacy while minimizing long-term side effects, considering the excellent prognosis often associated with LPHL. Regular follow-up and monitoring are essential after treatment to detect any potential recurrence early.